- Biocytogen Grants IDEAYA Exclusive Global Licensing Option for Potential First-in-Class B7H3/PTK7 Topoisomerase Inhibitor Payload Bispecific Antibody Drug Conjugate (BsADC)
- B7H3/PTK7 co-expression has been found in multiple solid tumor types, including lung, colorectal, and head and neck cancers with double-digit prevalence
- Reasonable combination opportunities with IDEAYA’s DNA damage repair (DDR) R&D product line including IDE161 (PARG)
- Plans to nominate candidate development projects in the second half of 2024
BEIJING, China and SOUTH SAN FRANCISCO, Calif.- (BUSINESS WIRE)– Biocytogen (Beijing) Medical Technology, an international biotechnology company focused on the development of new antibody/ADC therapies Co., Ltd. (Biocytogen, stock code: 02315.HK) announced that it has partnered with IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology precision medicine company dedicated to discovering and developing targeted therapeutic drugs, to develop the potential first-in-class B7H3 The /PTK7 BsADC project has reached an option and licensing agreement.
Dr. Shen Yuelei, Chairman and CEO of Biocytogen, said: “We are pleased to announce our collaboration with IDEAYA to explore the potential of combining our first-of-its-kind ADC with IDEAYA’s DDR small molecules. This collaboration leverages our advanced RenLite ® platform and proprietary linker-loading technology to improve the precision and effectiveness of ADC drugs. IDEAYA’s strong determination and extensive experience in drug development make us confident that this therapy can be rapidly advanced to benefit patients.”
Yujiro S. Hata, Chairman and CEO of IDEAYA Biosciences, said: “The potential first-in-class B7H3/PTK7 topoisomerase inhibitor payload BsADC project is expected to be developed as a monotherapy drug against multiple types of solid tumors, and Promote IDEAYA’s broader corporate strategy to achieve independent first-of-its-kind rational combinations at the intersection of ADCs and small molecule DDR therapies to bring greater benefits to patients.”
The agreement will grant IDEAYA an option to obtain exclusive global rights to Biocytogen’s potential first-in-class B7H3/PTK7 topoisomerase inhibitor payload BsADC project. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers with double-digit prevalence rates.
Under the terms of the agreement, Biocytopen will receive an upfront payment and, if IDEAYA exercises the option, Biocytó is entitled to receive option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and a single-digit share of net sales. . The potential transaction totals $406.5 million, including $100 million in clinical development and regulatory milestone payments.
Based on preclinical data, the potential first-in-class B7H3/PTK7 topoisomerase inhibitor payload BsADC project may be developed as a monotherapy drug or may be integrated with multiple projects in IDEAYA’s R&D pipeline targeting DDR therapies ( Including PARG inhibitor IDE161) as the basis for combined use. The development candidate drug nomination plan for the B7H3/PTK7 topoisomerase inhibitor payload BsADC project is scheduled to be completed in the second half of 2024.
About Biocytogen
Biocytogen (stock code: 02315.HK) is an international biotechnology company that drives the research and development of new drugs with innovative technology, and is committed to becoming the birthplace of new drugs in the world. Based on underlying gene editing technology, Biocytogen independently developed the RenMice ® (RenMab ® , RenLite ® , RenNano ® , RenTCR-mimic TM ) platform for fully human therapeutic monoclonal antibodies, bi/multispecific antibodies, Discovery of double anti-ADCs, nanobodies and TCR-like antibodies. Biocytogen is conducting large-scale drug development for more than 1,000 potentially druggable targets (the “Thousands of Rats and Tens of AntibodiesTM “ project), and has established a library of more than 400,000 fully human antibody sequences for global collaboration. As of December 31, 2023, Biocytogen has signed 103 drug cooperative development/authorization/transfer agreements, and reached 47 target project RenMice ® platform authorized development cooperation with companies, including multiple MNCs; many A clinical-stage antibody molecule has also reached external licensing cooperation. The company’s sub-brand BioMice® provides thousands of gene-edited animal and cell models, including target humanized mice, and also provides preclinical pharmacology and gene editing services to customers around the world. Biocytogen is headquartered in Beijing and has branches in China (Haimen, Jiangsu, Shanghai), the United States (Boston, San Francisco) and Heidelberg, Germany. For more information, please visit the official website https://www.biocytogen.com.cn/ .
About IDEAYA Biosciences
IDEAYA is an oncology precision medicine company dedicated to discovering and developing targeted therapeutic drugs for patient groups selected through molecular diagnostics. IDEAYA’s approach is to combine the ability to discover and validate translational biomarkers with drug development to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to emerging precision medicine targets such as synthetic lethality.
Disclaimer: The original version of this announcement is the officially authorized version. The translation is for convenience of understanding only. Please refer to the original text. The original version is the only legally binding version.
Contacts
Biocytogen Contact Information
Antibody Assets and Platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
IDEAYA Biosciences
Investor and Media Contact
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
